The Boston-based company's new medication, called Journavx, is being placed on a tier that means it might be costlier than ...

A research team has developed a non-opioid medication that shows promise in treating acute and chronic pain. The drug, known ...

New research has identified cannabis-derived terpenes—compounds that give plants their distinctive aroma—as effective ...

Congress and the Florida Legislature must eliminate cost disparities between opioid and non-opioid options.

During my time serving in the state legislature, I heard from numerous constituents impacted by the opioid crisis ...

Positive data from a pair of acute pain studies convinced the company that its drug, which works differently than existing ...

Chronic pain, which lasts for three months or longer, is difficult to treat. Many people rely on opioid pain medications, but ...

Collegium Pharmaceutical is executing on commercializing its drugs and growing sales. Click here to find out why COLL stock ...

Sen. Mark Kelly champions the PAIN Act to improve seniors' access to non-opioid pain treatments under Medicare.

Investing.com -- Vertex Pharmaceuticals Inc (NASDAQ: VRTX ).’s newly approved non-opioid pain medication, Journavx, has been included in UnitedHealth Group Inc (NYSE: UNH ).’s coverage, according to ...

Vertex Pharmaceuticals Inc.’s new non-opioid painkiller ... might be costlier than other pain treatments on UnitedHealth Group Inc.’s approved drug lists. The medication, called Journavx ...